Stocks
Gossamer Bio Financial Statements (GOSS) |
||||||||||
| Gossamer Biosmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 24.03.2020 | 26.02.2021 | 03.03.2022 | 17.03.2023 | 05.03.2024 | 12.08.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 102.6 | |||
| Operating Income, bln rub | -186.1 | -234.0 | -216.1 | -218.6 | -183.8 | -69.4 | ||||
| EBITDA, bln rub | ? | -178.9 | -207.3 | -214.5 | -215.4 | -172.2 | -62.5 | |||
| Net profit, bln rub | ? | -180.8 | -251.6 | -249.1 | -240.2 | -179.8 | -80.9 | |||
| OCF, bln rub | ? | -144.8 | -176.4 | -188.9 | -187.0 | -159.2 | -3.87 | |||
| CAPEX, bln rub | ? | 6.57 | 24.9 | 1.62 | 0.475 | 0.000 | 116.4 | |||
| FCF, bln rub | ? | -151.4 | -201.2 | -190.5 | -187.5 | -159.2 | -120.2 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 182.5 | 210.6 | 216.0 | 218.5 | 183.8 | 163.2 | ||||
| Cost of production, bln rub | 3.09 | 4.27 | 5.17 | 4.43 | 4.39 | 4.09 | ||||
| R&D, bln rub | 143.4 | 160.9 | 170.3 | 170.9 | 145.3 | 128.1 | ||||
| Interest expenses, bln rub | 0.000 | 12.7 | 19.4 | 13.9 | 13.5 | 12.6 | ||||
| Assets, bln rub | 426.6 | 539.4 | 343.7 | 272.5 | 311.9 | 373.4 | ||||
| Net Assets, bln rub | ? | -334.2 | -577.5 | -811.5 | -1 032 | 62.8 | 81.5 | |||
| Debt, bln rub | 39.6 | 183.7 | 185.2 | 225.7 | 212.5 | 198.9 | ||||
| Cash, bln rub | 401.8 | 512.6 | 325.2 | 255.7 | 296.4 | 354.5 | ||||
| Net debt, bln rub | -362.3 | -328.9 | -140.0 | -29.9 | -84.0 | -155.6 | ||||
| Ordinary share price, rub | 15.6 | 9.67 | 11.3 | 2.17 | 0.913 | 0.510 | ||||
| Number of ordinary shares, mln | 54.7 | 68.5 | 74.8 | 84.6 | 152.6 | 226.2 | ||||
| Market cap, bln rub | 856 | 662 | 846 | 184 | 139 | 115 | ||||
| EV, bln rub | ? | 493 | 334 | 706 | 154 | 55 | -40 | |||
| Book value, bln rub | -334 | -578 | -812 | -1 032 | 63 | 82 | ||||
| EPS, rub | ? | -3.30 | -3.67 | -3.33 | -2.84 | -1.18 | -0.36 | |||
| FCF/share, rub | -2.77 | -2.94 | -2.55 | -2.22 | -1.04 | -0.53 | ||||
| BV/share, rub | -6.10 | -8.43 | -10.8 | -12.2 | 0.41 | 0.36 | ||||
| EBITDA margin, % | ? | -60.9% | ||||||||
| Net margin, % | ? | -78.8% | ||||||||
| FCF yield, % | ? | -17.7% | -30.4% | -22.5% | -102.2% | -114.3% | -104.2% | |||
| ROE, % | ? | 54.1% | 43.6% | 30.7% | 23.3% | -286.5% | -99.2% | |||
| ROA, % | ? | -42.4% | -46.6% | -72.5% | -88.2% | -57.6% | -21.7% | |||
| P/E | ? | -4.73 | -2.63 | -3.40 | -0.76 | -0.77 | -1.43 | |||
| P/FCF | -5.65 | -3.29 | -4.44 | -0.98 | -0.88 | -0.96 | ||||
| P/S | ? | 1.12 | ||||||||
| P/BV | ? | -2.56 | -1.15 | -1.04 | -0.18 | 2.22 | 1.42 | |||
| EV/EBITDA | ? | -2.76 | -1.61 | -3.29 | -0.71 | -0.32 | 0.64 | |||
| Debt/EBITDA | 2.02 | 1.59 | 0.65 | 0.14 | 0.49 | 2.49 | ||||
| R&D/CAPEX, % | 2 184% | 646.4% | 10 504% | 35 983% | 110.0% | |||||
| CAPEX/Revenue, % | 113.5% | |||||||||
| Gossamer Bio shareholders | ||||||||||
